{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:04:40Z","timestamp":1789646680640,"version":"4.0.0"},"reference-count":37,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,12]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"\n Objectives<\/jats:title>\n The purpose of this study was to establish the frequency of Medical Dictionary for Regulatory Activities (MedDRA) utilisation in gastrointestinal and abdominal surgical trials, identify predictors of its adoption and quantify the association between MedDRA use and adverse event (AE) reporting quality as measured by Completeness scores, registry\u2013publication Concordance and overall Transparency indices.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Cross-sectional analysis of matched randomised controlled trial registry\u2013publication pairs.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n 116 gastrointestinal and abdominal surgery randomised controlled trials registered on ClinicalTrials.gov with results posted between September 2009 and December 2024 and an associated peer-reviewed publication.<\/jats:p>\n <\/jats:sec>\n \n Primary and secondary outcome measures<\/jats:title>\n Primary outcomes were differences in AE reporting quality between MedDRA-documenting and non-documenting trials, measured using Harms Reporting Completeness Score (0\u20138), Concordance Score (0\u20137) and Harms Transparency Index (0\u201315). Secondary outcomes included prevalence of MedDRA adoption and predictors of MedDRA documentation via univariable logistic regression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 116 included trials, only 22 (18.8%) explicitly documented MedDRA use. Industry-funded trials (OR=29.32, 95% CI 8.94 to 118.50, p<0.001) and those with at least one US site (OR=4.59, 95% CI 1.22 to 30.02, p=0.050) demonstrated significantly higher rates of MedDRA adoption. Trials documenting MedDRA use demonstrated significantly improved reporting across all three score parameters: Completeness score (p<0.001), Concordance score (p=0.002) and Transparency Index (p<0.001). MedDRA use was also associated with lower rates of registry\u2013publication discordance across key safety metrics: serious AE participant count registry\u2013publication discordance was 59.1% in MedDRA-documenting trials and 85.1% in non-MedDRA trials; mortality reporting discordance was 60.0% in MedDRA trials and 82.1% in non-MedDRA trials.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Despite strong association with greater AE reporting completeness and registry\u2013publication concordance, MedDRA adoption in gastrointestinal and abdominal surgical trials remains below 20%, concentrated among industry-funded studies. The predominance of unstandardised terminology and free-text strategies contributes to reporting inadequacies that complicate evidence synthesis and undermine evidence-based surgical practice. Journals, funding agencies, academic institutions and researchers should prioritise the adoption of standardised AE terminology to enhance transparency and improve surgical research.<\/jats:p>\n <\/jats:sec>\n \n PROSPERO registration number<\/jats:title>\n CRD420251081191.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117978","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:45:34Z","timestamp":1789645534000},"page":"e117978","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["MedDRA adoption and adverse event reporting quality in gastrointestinal and abdominal surgery randomised controlled trials: a cross-sectional analysis"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5550-3614","authenticated-orcid":false,"given":"Nicholas C","family":"Camasso","sequence":"first","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-309X","authenticated-orcid":false,"given":"Kohl","family":"Kirby","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8906-1345","authenticated-orcid":false,"given":"Noah","family":"Calvert","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8864-1158","authenticated-orcid":false,"given":"John","family":"Stroup","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6539-2569","authenticated-orcid":false,"given":"Ryan","family":"Langerman","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Vassar","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026091704451381000_16.9.e117978.1","unstructured":"Best practices guidelines. ACS. Available: https:\/\/www.facs.org\/quality-programs\/trauma\/quality\/best-practices-guidelines\/ [Accessed 27 Dec 2025]."},{"key":"2026091704451381000_16.9.e117978.2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2025.04.008","article-title":"EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease","volume":"83","author":"Thabut","year":"2025","journal-title":"J Hepatol"},{"key":"2026091704451381000_16.9.e117978.3","unstructured":"Clinical practice guidelines. Available: https:\/\/www.ascrsu.com\/ascrs\/index\/ASCRS-Toolkit\/Clinical_Practice_Guidelines [Accessed 24 Jan 2026]."},{"key":"2026091704451381000_16.9.e117978.4","unstructured":"CONSORT harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials. Available: https:\/\/www.equator-network.org\/reporting-guidelines\/consort-harms\/ [Accessed 24 Jan 2026]."},{"key":"2026091704451381000_16.9.e117978.5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.amjsurg.2023.07.017","article-title":"How surgeons use risk calculators and non-clinical factors for informed consent and shared decision making: A qualitative study","volume":"226","author":"Panton","year":"2023","journal-title":"Am J Surg"},{"key":"2026091704451381000_16.9.e117978.6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00268-014-2776-8","article-title":"Reporting of adverse events in surgical trials: critical appraisal of current practice","volume":"39","author":"Rosenthal","year":"2015","journal-title":"World J Surg"},{"key":"2026091704451381000_16.9.e117978.7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.42195","article-title":"Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma","volume":"6","author":"Najjar","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026091704451381000_16.9.e117978.8","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1177\/03635465241259738","article-title":"Transparency Matters: Assessing Harms Reporting Compliance in Randomized Controlled Trials Underpinning the AAOS Clinical Practice Guideline for Anterior Cruciate Ligament Injuries","volume":"52","author":"Brown","year":"2024","journal-title":"Am J Sports Med"},{"key":"2026091704451381000_16.9.e117978.9","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/j.jse.2022.06.021","article-title":"Harms-related data are poorly reported among randomized controlled trials underpinning the American Academy of Orthopaedic Surgeons clinical practice guideline recommendations for rotator cuff injuries","volume":"31","author":"Anderson","year":"2022","journal-title":"J Shoulder Elbow Surg"},{"key":"2026091704451381000_16.9.e117978.10","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.arth.2022.06.004","article-title":"Inadequate Reporting of Complications in Randomized Controlled Trials Cited as Supporting Evidence Underpinning AAOS CPG Recommendations for Hip and Knee Osteoarthritis: Application of the CONSORT Harms Checklist","volume":"37","author":"Anderson","year":"2022","journal-title":"J Arthroplasty"},{"key":"2026091704451381000_16.9.e117978.11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bja.2025.02.015","article-title":"Discrepancies in adverse event reporting for ketamine trials","volume":"134","author":"Rea","year":"2025","journal-title":"Br J Anaesth"},{"key":"2026091704451381000_16.9.e117978.12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-24290-3","article-title":"Systematic review with cross sectional comparative analysis identifies adverse event reporting discrepancies between ClinicalTrials.gov and published glaucoma randomized controlled trials","volume":"15","author":"Elghzali","year":"2025","journal-title":"Sci Rep"},{"key":"2026091704451381000_16.9.e117978.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3959"},{"key":"2026091704451381000_16.9.e117978.14","doi-asserted-by":"crossref","first-page":"111406","DOI":"10.1016\/j.jclinepi.2024.111406","article-title":"Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review","volume":"173","author":"Beytout","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026091704451381000_16.9.e117978.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0430-4","article-title":"Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles","volume":"13","author":"Tang","year":"2015","journal-title":"BMC Med"},{"key":"2026091704451381000_16.9.e117978.16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1071100719879930","article-title":"Variability in the Reporting Terminology of Adverse Events and Complications in Ankle Fracture Fixation: A Systematic Review","volume":"41","author":"St George","year":"2020","journal-title":"Foot Ankle Int"},{"key":"2026091704451381000_16.9.e117978.17","unstructured":"MedDRA. Available: https:\/\/www.meddra.org\/ [Accessed 27 Dec 2025]."},{"key":"2026091704451381000_16.9.e117978.18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.36849\/JDD.9448","article-title":"Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024","volume":"25","author":"Fat","year":"2026","journal-title":"J Drugs Dermatol"},{"key":"2026091704451381000_16.9.e117978.19","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2025-003636","article-title":"Postmarketing analysis of sotatercept: identifying serious unlabelled events","volume":"12","author":"Cao","year":"2025","journal-title":"Open Heart"},{"key":"2026091704451381000_16.9.e117978.20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/JS9.0000000000003314","article-title":"Systematic analysis and mechanistic investigation of cardiac adverse events associated with antibody-drug conjugates using FAERS database","volume":"112","author":"Zheng","year":"2026","journal-title":"Int J Surg"},{"key":"2026091704451381000_16.9.e117978.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110638"},{"key":"2026091704451381000_16.9.e117978.22","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35962","article-title":"Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)","volume":"131","author":"Menzies","year":"2025","journal-title":"Cancer"},{"key":"2026091704451381000_16.9.e117978.23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40264-025-01582-1","article-title":"The Development and Use of Office of New Drugs Custom Medical Queries for Safety Analyses of Clinical Trial Data","volume":"48","author":"Proestel","year":"2025","journal-title":"Drug Saf"},{"key":"2026091704451381000_16.9.e117978.24","unstructured":"PROSPERO. Available: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251081191 [Accessed 23 Dec 2025]."},{"key":"2026091704451381000_16.9.e117978.25","unstructured":"OSF. Available: https:\/\/osf.io\/uqpmc\/overview?view_only=438362990977431989f5f74479965c81 [Accessed 29 Jan 2026]."},{"key":"2026091704451381000_16.9.e117978.26","unstructured":"42 CFR part 11 -- clinical trials registration and results information submission. Available: https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-11 [Accessed 22 Oct 2025]."},{"key":"2026091704451381000_16.9.e117978.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"2026091704451381000_16.9.e117978.28","first-page":"145","article-title":"Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices","volume":"40","author":"Hendrickson","year":"2026","journal-title":"Pharmaceut Med"},{"key":"2026091704451381000_16.9.e117978.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-025-02486-5","article-title":"Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications","volume":"25","author":"Boyne","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"2026091704451381000_16.9.e117978.30","first-page":"2025","article-title":"Assessing the completeness of safety reporting in clinical trials of regional anesthesia interventions: a registry-publication comparison systematic review","volume":"9","author":"McCormick","year":"2025","journal-title":"Reg Anesth Pain Med"},{"key":"2026091704451381000_16.9.e117978.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031138","article-title":"Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications","volume":"9","author":"Wong","year":"2019","journal-title":"BMJ Open"},{"key":"2026091704451381000_16.9.e117978.32","doi-asserted-by":"publisher","DOI":"10.7326\/M13-0480"},{"key":"2026091704451381000_16.9.e117978.33","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.asmr.2022.10.010","article-title":"Harms Reporting Is Inadequate in Systematic Reviews Regarding Hip Arthroscopy","volume":"5","author":"Peters","year":"2023","journal-title":"Arthrosc Sports Med Rehabil"},{"key":"2026091704451381000_16.9.e117978.34","unstructured":"ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT00528970?cond=Ileus&aggFilters=results:with,status:com&rank=2&tab=results#adverse-events [Accessed 29 Dec 2025]."},{"key":"2026091704451381000_16.9.e117978.35","unstructured":"ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT03852524?cond=Ileus&aggFilters=results:with,status:com&rank=5&tab=results#adverse-events [Accessed 29 Dec 2025]."},{"key":"2026091704451381000_16.9.e117978.36","unstructured":"ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/study\/NCT00401375?cond=Ileus&aggFilters=results:with,status:com&page=2&rank=13&tab=results#adverse-events [Accessed 29 Dec 2025]."},{"key":"2026091704451381000_16.9.e117978.37","unstructured":"Office for human research protections (OHRP). Available: https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/index.html [Accessed 24 Jan 2026]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:45:45Z","timestamp":1789645545000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,17]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-117978"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117978","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}